P-12 Marrow progenitors in myelodysplastic syndrome (MDS) demonstrate an aberrant cell cycle and DNA damage

David R. Head(University of Southern California), Keith Shults(Center for Innovation), James W. Jacobberger(University Hospitals Cleveland Medical Center), Sara A. McClintock-Treep(Vanderbilt University), Leanne A. Flye(Center for Innovation), Fouad Boulos(Vanderbilt University), Feng Jiang, R C Briggs(Vanderbilt University), S. Goodman(Vanderbilt University Medical Center), Madan Jagasia(Vanderbilt University Medical Center), Greg Stelzer(Center for Innovation)

Leukemia Research

January 1, 2005

10.1016/s0145-2126(05)80076-1

Cited by 0

Related Papers

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report

|Biology of Blood and Marrow Transplantation|2014|5.4k

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

|Blood|2000|1.6k

Age and acute myeloid leukemia

|Blood|2006|1.4k

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

|Blood|1997|869

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

|Journal of Clinical Oncology|1990|786